The identification of potent and selective imidazole-based inhibitors of B-Raf kinase

被引：187

作者：

Takle, AK

Brown, MJB

Davies, S

Dean, DK

Francis, G

Gaiba, A

Hird, AW

King, FD

Lovell, PJ

Naylor, A

Reith, AD

Steadman, JG

Wilson, DM

机构：

[1] GlaxoSmithKline Pharmaceut, Dept Med Chem, Harlow CM19 5AW, Essex, England

[2] GlaxoSmithKline Pharmaceut, GI Ctr Excellence Drug Discovery, Harlow CM19 5AW, Essex, England

[3] GlaxoSmithKline Pharmaceut, Med R&D Ctr, Dept Screening & Cpd Profiling, Stevenage SG1 2NY, Herts, England

[4] GlaxoSmithKline Pharmaceut, Med R&D Ctr, Dept High Throughput Biol, Stevenage SG1 2NY, Herts, England

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2006年 / 16卷 / 02期

关键词：

B-Raf; imidazole;

D O I：

10.1016/j.bmcl.2005.09.072

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A novel triarylimidazole derivative, SB-590885 (33), bearing a 2,3-dihydro-1H-inden-1-one oxime substituent has been identified as a potent and extremely selective inhibitor of B-Raf kinase. (c) 2005 Elsevier Ltd. All rights reserved.

引用

页码：378 / 381

页数：4

共 12 条

[1]

Adams JL, 2001, PROGR MED CHEM, V38, P1, DOI 10.1016/S0079-6468(08)70091-2

[2]

Chang FM, 2003, INT J ONCOL, V22, P469

[3] Mutations of the BRAF gene in human cancer [J].

Davies, H ;

Bignell, GR ;

Cox, C ;

Stephens, P ;

Edkins, S ;

Clegg, S ;

Teague, J ;

Woffendin, H ;

Garnett, MJ ;

Bottomley, W ;

Davis, N ;

Dicks, N ;

Ewing, R ;

Floyd, Y ;

Gray, K ;

Hall, S ;

Hawes, R ;

Hughes, J ;

Kosmidou, V ;

Menzies, A ;

Mould, C ;

Parker, A ;

Stevens, C ;

Watt, S ;

Hooper, S ;

Wilson, R ;

Jayatilake, H ;

Gusterson, BA ;

Cooper, C ;

Shipley, J ;

Hargrave, D ;

Pritchard-Jones, K ;

Maitland, N ;

Chenevix-Trench, G ;

Riggins, GJ ;

Bigner, DD ;

Palmieri, G ;

Cossu, A ;

Flanagan, A ;

Nicholson, A ;

Ho, JWC ;

Leung, SY ;

Yuen, ST ;

Weber, BL ;

Siegler, HF ;

Darrow, TL ;

Paterson, H ;

Marais, R ;

Marshall, CJ ;

Wooster, R .

NATURE, 2002, 417 (6892) :949-954

[4] Specificity and mechanism of action of some commonly used protein kinase inhibitors [J].

Davies, SP ;

Reddy, H ;

Caivano, M ;

Cohen, P .

BIOCHEMICAL JOURNAL, 2000, 351 (351) :95-105

[5]

DEAN DK, 2002, Patent No. 0224680

[6] Regulation of stress-induced cytokine production by pyridinylimidazoles; Inhibition of CSBP kinase [J].

Gallagher, TF ;

Seibel, GL ;

Kassis, S ;

Laydon, JT ;

Blumenthal, MJ ;

Lee, JC ;

Lee, D ;

Boehm, JC ;

FierThompson, SM ;

Abt, JW ;

Soreson, ME ;

Smietana, JM ;

Hall, RF ;

Garigipati, RS ;

Bender, PE ;

Erhard, KF ;

Krog, AJ ;

Hofmann, GA ;

Sheldrake, PL ;

McDonnell, PC ;

Kumar, S ;

Young, PR ;

Adams, JL .

BIOORGANIC & MEDICINAL CHEMISTRY, 1997, 5 (01) :49-64

[7]

HCIMBROOK DC, 1998, 3793 AM ASS CANC RES

[8] The Ras-Raf-MEK-ERK pathway in the treatment of cancer [J].

Hilger, RA ;

Scheulen, ME ;

Strumberg, D .

ONKOLOGIE, 2002, 25 (06) :511-518

[9] Differential activation of MAPK/ERK and p38/SAPK in neurones and glia following focal cerebral ischaemia in the rat [J].

Irving, EA ;

Barone, FC ;

Reith, AD ;

Hadingham, SJ ;

Parsons, AA .

MOLECULAR BRAIN RESEARCH, 2000, 77 (01) :65-75

[10] Intravenous administration of MEK inhibitor U0126 affords brain protection against forebrain ischemia and focal cerebral ischemia [J].

Namura, S ;

Iihara, K ;

Takami, S ;

Nagata, I ;

Kikuchi, H ;

Matsushita, K ;

Moskowitz, MA ;

Bonventre, JV ;

Alessandrini, A .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (20) :11569-11574

← 1 2 →